Regardless of the cause, these results provide a proof-of-concept that Pin1-FOXM1-blocking peptides are functional against melanoma progression in a physiological setting ex vivo and are a therefore potentially applicable therapeutic tool to complement BRAF/MEK inhibitors to clinically target metastatic melanoma (Figure 7e). This evidence concerns the gene FOXM1 and metastatic melanoma.